DRTECH Corporation appears in FDA records as the applicant for a stationary X-ray system cleared through the Traditional 510(k) pathway. The submission K260227 was received January 26, 2026 and decided September 8, 2026 with a Substantially Equivalent decision, a Class II designation, product code KPR and regulation 21 CFR 892.1680 under the Radiology panel. The device name in the record lists four EXSYS DEXi configurations: S40S, S40P, S40T and S50H. The filing correspondence carries an August 2026 date, and the record notes a Summary rather than a statement, with no third-party review. [1][4][7]

The cleared device and its listed configurations

The K260227 record identifies the trade device as EXSYS DEXi in four named variants: EXSYS DEXi-S40S, EXSYS DEXi-S40P, EXSYS DEXi-S40T and EXSYS DEXi-S50H. The device name string is truncated after the fourth variant in the FDA extract, so any further configurations are not established by these sources. Classification is Stationary X-Ray System, device class 2, regulation number 892.1680, product code KPR, advisory committee Radiology. [1][3][6]

DRTECH's own product page describes EXSYS DEXI as a digital X-ray system with Auto Tracking and Auto Alignment technology, a DRTECH generator, and a customizable configuration option. Those descriptions are the manufacturer's published product statements, not FDA findings, and the page does not map them to individual model suffixes. [5]

Submission timeline and review characteristics

The FDA extract gives a date received of January 26, 2026 and a decision date of September 8, 2026, with decision code SESE and description Substantially Equivalent. The clearance type is Traditional, the third-party flag is N, and the submission includes a Summary. The clearance letter in the FDA document library is dated August 11, 2026 and recorded as received August 12, 2026. [1][4][7]

One independent index reports the K260227 review as lasting 225 days; that figure is the index's own calculation and is not stated in the FDA extract. [8]

Earlier EXSYS DEXi filing in the record

A separate FDA clearance letter, K233530 dated July 26, 2024, addresses EXSYS DEXi configurations with suffixes such as D401S-FRM, A401S-FRM, D402S-FRM, A402S-FRM, D401P-FRM and A401P-FRM, and is addressed to DRTECH Corporation care of Kim Hanbyul at the Seongnam-si address. That letter references FDA guidance documents on device software functions, X-ray conformance with IEC standards, cybersecurity and pediatric information, and states that risk analysis was completed and risk controls implemented. [9]

An index entry lists a 2024-10-23 EXSYS DEXi record for DRTECH Corporation with additional suffixes including FRM and FRA variants; the entry does not supply a K number, so it is not treated here as a confirmed separate clearance. [4]

Applicant identity and record scope

DRTECH Corporation is the applicant name on K260227, with a Seongnam-Si, Republic of Korea filing address and contact Hanbyul Kim. The filing address is a correspondence address in the FDA record and does not establish a corporate headquarters. No parent, brand owner or affiliate relationship is verified in these sources. [1][5]

The supplied portfolio snapshot contains one linked 510(k) record, K260227, and the decision count for that collection is one Substantially Equivalent decision; the smaller record sample likewise holds that single entry. These counts describe the supplied filings as of the snapshot date and say nothing about total company sales, total portfolio or safety performance. No recall records appear in the snapshot. [1][6]